GLP-1 Agonists and Endoscopy: GI Specialists Issue Statement
In their statement, the GI specialists noted that they are familiar with safety issues regarding endoscopy in patients with gastroparesis.
In their statement, the GI specialists noted that they are familiar with safety issues regarding endoscopy in patients with gastroparesis.
Brenzavvy is an oral sodium-glucose cotransporter 2 inhibitor.
The approval of empagliflozin for pediatric T2DM was based on data from the phase 3 DINAMO trial.
Semaglutide, a GLP-1 receptor agonist, is currently approved under 3 brand names: Ozempic, Rybelsus, and Wegovy.
Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.
The approval was based on data from a clinical program that included 23 clinical trials enrolling more than 5000 adults with type 2 diabetes mellitus.
The use of recalled products may lead to signs and symptoms of hypothyroidism.
A recent posting on the FDA’s Drug Shortages tracker indicates that the product has been discontinued.
Tirosint-SOL is approved for the treatment of hypothyroidism and for pituitary thyrotropin suppression.